Tenaya Therapeutics reports Q3 net loss of $25.6M; DSMB clears dose escalation for TN-201 gene therapy

Tenaya Therapeutics, Inc.

2024-Q3 EPS reported -$1.04

Net loss of $25.6M ($0.30 per share) vs $29.1M ($0.39) in Q3 2023.
Cash and investments $79.5M; runway expected into H2 2025.
DSMB recommended dose escalation to 6E13 vg/kg for TN-201 in MyPEAK-1; initial Cohort 1 data expected Dec 2024.
Expanded MyPEAK-1 eligibility to include obstructive HCM patients and those without ICDs; baseline biopsy added.
Entered $45M undrawn credit facility with Silicon Valley Bank in August 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.